ION Acquisition Corp 3 Ltd. (IACC) News
Filter IACC News Items
IACC News Results
| Date | Symbol | Company | Title | Start | End | Change | POWR Rating | ||
|---|---|---|---|---|---|---|---|---|---|
| Loading, please wait... | |||||||||
Latest IACC News From Around the Web
Below are the latest news stories about ION ACQUISITION CORP 3 LTD that investors may wish to consider to help them evaluate IACC as an investment opportunity.
Day One Receives Orphan Designation from the European Commission for DAY101 for the Treatment of GliomaSOUTH SAN FRANCISCO, Calif., June 21, 2021 (GLOBE NEWSWIRE) -- Day One Biopharmaceuticals, a clinical-stage biopharmaceutical company dedicated to developing and commercializing targeted therapies for patients of all ages with genetically defined cancers, today announced that the European Commission has granted orphan designation for the Company’s lead product candidate, DAY101, for the treatment of glioma. The designation was based on a positive opinion from the European Medicines Agency Commit |